From Nasdaq Inc.:

Alnylam Pharmaceuticals Inc. reported 40% total TTR annual growth for ONPATTRO and AMVUTTRA in 2023, with global net product revenues of $355 million and $558 million, respectively. Over 4,060 patients worldwide were receiving commercial ONPATTRO or AMVUTTRA by the end of 2023. For GIVLAARI and OXLUMO, the company saw 35% total Ultra-Rare annual growth in 2023, with $219 million and $110 million in net product revenues, respectively. Over 650 patients were receiving commercial GIVLAARI, while over 430 patients were receiving commercial OXLUMO by year-end 2023. Alnylam had $2.4 billion in cash, cash equivalents, and marketable securities at the end of 2023, compared to $2.2 billion at the end of 2022.



Read more: Alnylam Pharma Announces Preliminary 2023 Global Net Product Revenue